Onychomycosis and diabetes
- 10 September 2009
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 23 (10), 1119-1122
- https://doi.org/10.1111/j.1468-3083.2009.03225.x
Abstract
This study aims to discuss factors specific to diabetics in the diagnosis and treatment of onychomycosis.Onychomycosis has the potential to cause severe complications in diabetics and should be treated promptly. The existence of comorbid conditions and potential for drug-drug interactions complicates the selection of an appropriate treatment regimen. The role of Candida in onychomycosis is controversial but may be of increased significance in the diabetic population due to an underlying vulnerability to this organism.Terbinafine is an excellent choice in diabetics due to its low risk of drug-drug interaction and proven efficacy against the typical pathogens that cause onychomycosis. Itraconazole, while an effective treatment for onychomycosis, is not a first-choice therapy due to its black-box cardiac warning and numerous drug interactions. Larger studies are needed in diabetics to determine the frequency of candidal nail infections.Keywords
This publication has 22 references indexed in Scilit:
- Metabolic syndrome associated with toenail onychomycosis in Taiwanese with diabetes mellitusInternational Journal of Dermatology, 2008
- Assessment and treatment of diabetic foot ulcerInternational Journal of Clinical Practice, 2007
- Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitusJournal of the European Academy of Dermatology and Venereology, 2006
- Prediction of Diabetic Foot Ulcer Occurrence Using Commonly Available Clinical InformationDiabetes Care, 2006
- Safety of Itraconazole in Diabetic PatientsDermatology, 1999
- Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre surveyBritish Journal of Dermatology, 1998
- Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernailJournal of the American Academy of Dermatology, 1998
- Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada ‐ a multicenter survey of 2001 patientsInternational Journal of Dermatology, 1997
- Clinical and mycological diagnostic aspects of onychomycoses and dermatomycosesClinical and Experimental Dermatology, 1992